GPT and metabolic dysfunction-associated steatotic liver disease: Chong et al. (88) and Derosa et al. (89) found that NAFLD patients treated with VSL#3® had a decreased AST/ALT ratio and hs-CRP level and improved IR and endothelial dysfunction.